Redcare Pharmacy : Präsentation Earnings Call Q3 2024 (Englisch)

Q3 2024 Earnings call presentation.

SEVENUM | 5 november 2024

Presenting live from Sevenum.

Today's

presenters.

Olaf Heinrich,	Jasper Eenhorst,
Chief Executive Officer.	Chief Financial Officer.

3

Greetings from Pilsen.

4

Today's agenda.

• Financial performance.

• E-Rxupdate.

• Outlook and guidance.

5

1

Financial performance.

6

Financial performance

9M 2024 financial highlights.

Fast growth with record sales continued.

Group sales up 34% in 9M 2024, reaching EUR 1.7bn. Excluding MediService (consolidated since May 2023), growth was 23%.

Non-Rx growth of 20% to EUR 1.2bn.

+18% in the DACH Segment and +26% in the International Segment.

Exceptional Rx momentum in Germany.

7% in Q1, -> 37% in Q2, -> 81% in Q3 of which 108% in September.

Adj. EBITDA 2% in Q3, 2.3% YTD.

Continued solid performance across the Group, with more Rx marketing in Germany throughout the year.

Full-year guidance updated on 3 October; decision to accelerate based on very convincing e-Rx metrics.

7

KEY FINANCIALS | 9M sales Sales

Double-digit growth continues.

Total	DACH
+33.8%	+35.8%
Non-Rx:		Non-Rx:
+20.2%		+18.3%
EUR	EUR	RX:
+79.8%
1,695M	1,376M
EUR	EUR
1,267M	1,013M

9M 2023

9M 2024

9M 2023

9M 2024

International

Non-Rx:

25.7%

EUR

EUR 319M 254M

9M 2023

9M 2024

8

Rx update

Exceptional growth, dynamic acceleration of our Rx sales in Germany.

Rx growth from 7% in Q1, to 37% in Q2, to 81% in Q3 and accelerating to 108% in September.

Redcare Germany Rx sales

7%

37%

81%

Nationwide adoption of e-Rx

Go-live of CardLink

Summer break, less marketing

108%

Source: Redcare Pharmacy

9

Non-financial kpiS

Approaching 12M active customers, basket value up.

Number of customers

		69
	+0.4M	Net Promoter Score
	+0.4M	Q3 2024 (Q3 2023: 74)
	+0.3M
	11.9M
	+0.4M
10.5M	+1.4M	€ 61.86
Sep 2023	Sep 2024	Average shopping basket value
Q3 2024 (Q3 2023: € 60.21)

Note: due to rounding, total may differ from sum of quarters.

10